Sign in
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
Journal article   Peer reviewed

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

Michael L. Wang, Wojciech Jurczak, Mats Jerkeman, Judith Trotman, Pier L. Zinzani, David Belada, Carola Boccomini, Ian W. Flinn, Pratyush Giri, Andre Goy, …
The New England journal of medicine, Vol.386(26), pp.2482-2494
30/06/2022
PMID: 35657079

Abstract

Hematology Leukemia Lymphoma Oncology Treatments in Oncology
A trial involving 523 patients with mantle-cell lymphoma randomly assigned patients to receive bendamustine plus rituximab or these drugs plus ibrutinib. At a median follow-up of 7 years, the median progression-free survival with ibrutinib was nearly 81 months, as compared with 53 months without ibrutinib.

Details